SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced a poster presentation of preclinical data for its CMV…

Evaxion A/S · 6-K filed Jul 1, 2026 at 08:05 ET

At the news

NEUTRALIMPACT 3/10

6-K filed Jul 1, 2026 at 08:05 ET

Evaxion announced a poster presentation of preclinical data for its CMV vaccine candidate EVX-V1 at the International Herpesvirus Workshop on July 12, 2026. The data will guide final antigen selection for the candidate, which combines AI-discovered and AI-optimized antigens. This is a routine pipeline update with no financial or clinical data disclosed.

  • Evaxion will present preclinical data for CMV vaccine candidate EVX-V1 at IHW 2026 in Montreal on July 12, 2026.
  • EVX-V1 is a multi-component vaccine combining novel AI-discovered antigens with AI-optimized versions of established CMV antigens.
  • No CMV vaccine has been approved to date; the CMV treatment market was valued at $474.6M in 2023 with 6.6% CAGR forecast.
  • The presentation will guide final antigen selection for a broadly protective CMV vaccine candidate.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access